metricas
covid
Buscar en
Annals of Hepatology
Toda la web
Inicio Annals of Hepatology O-12 MIR-181A AS A BIOMARKER OF FIBROSIS IN NON-ALCOHOLIC FATTY LIVER DISEASE
Journal Information
Vol. 24. Issue S1.
Abstracts of the 2021 Annual meeting of the ALEH (Asociación Latinoamericana para el Estudio del Hígado)
(September 2021)
Share
Share
Download PDF
More article options
Vol. 24. Issue S1.
Abstracts of the 2021 Annual meeting of the ALEH (Asociación Latinoamericana para el Estudio del Hígado)
(September 2021)
Open Access
O-12 MIR-181A AS A BIOMARKER OF FIBROSIS IN NON-ALCOHOLIC FATTY LIVER DISEASE
Visits
598
Rodrigo Vieira Costa Lima1, Fernanda de Mello Malta1, José Tadeu Stefano1, João Renato Pinho1, Flair José Carrilho1, Claudia Pinto Marques Souza de Oliveira1
1 Division of Clinical (LIM-07), Department of Gastroenterology, University of São Paulo School of Medicine
This item has received

Under a Creative Commons license
Article information
Special issue
This article is part of special issue:
Vol. 24. Issue S1

Abstracts of the 2021 Annual meeting of the ALEH (Asociación Latinoamericana para el Estudio del Hígado)

More info
Introduction

Non-Alcoholic Fatty Liver Disease (NAFLD) covers a wide spectrum of disease, ranging from simple steatosis to cirrhosis. Liver biopsy is still the gold standard for assessing fibrosis, but there is a need to seek non-invasive biomarkers that can also be efficient in predicting fibrosis.

Objectives

To evaluate the role of microRNAs miR-21, miR-29a, miR-122, miR-155 and miR-181a in the phenotypic expression of NAFLD, correlating their serum levels with the different stages of the disease.

Methods

Cross-sectional study carried out on 108 NAFLD patients diagnosed by liver biopsy. In the histological analysis, the degrees of fibrosis and NAFLD activity score (NAS) were obtained. The FIB-4 and NAFLD fibrosis score were calculated and compared with the degree of fibrosis by biopsy. The comparison between the distributions of microRNA values ​​according to the presence or absence of clinically expressed fibrosis (F2-4) was performed. The serum expression of microRNAs was also compared with the NAS of the biopsy. A multivariate logistic regression analysis was performed to build a score for predicting fibrosis using FIB-4 and Ln (miR-181a) as independent variables.

Results

Among the microRNAs studied, only miR-181a showed a statistical difference between patients with clinically expressed fibrosis and those without fibrosis (F0-F1) determined by liver biopsy (p = 0.017). FIB-4 revealed an AUC on the ROC curve of 0.667 to predict clinically expressed fibrosis (F2-F4). When assessed using the score in association with Ln (miR-181a), there was an improvement in the ROC curve, with AUC of 0.71. There was no correlation between the serum levels of microRNAs miR-21, miR-29a, miR-122, miR-155 and miR-181a with the degrees of inflammatory activity determined by NAS.

Conclusion

miR-181a can be used as a non-invasive method of predicting fibrosis in NAFLD, and an association of biomarkers has the potential to increase the accuracy of each method alone.

Full text is only aviable in PDF
Download PDF
Article options
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos